Products & Services · Total revenues
Otezla — Total revenues
Amgen Otezla — Total revenues decreased by 95.0% to $431M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 94.7%, from $8.15B to $431M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates strong market adoption or successful commercial execution, while a decrease may signal increased competition or patent expiration.
Detailed definition
This represents the total gross sales generated by a specific pharmaceutical product line within the company's portfolio...
Peer comparison
Comparable to product-level revenue reporting in other major biopharmaceutical companies.
Metric ID:
amgn_segment_otezla_total_revenuesHistorical Data
40 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.53B | $534M | $6.71B | $609M | $6.85B | $630M | $6.24B | $451M | $6.59B | $594M | $6.65B | $627M | $6.84B | $616M | $6.11B | $392M | $6.99B | $600M | $6.9B | $567M | $8.2B | $629M | $7.45B | $394M | $8.39B | $544M | $8.5B | $564M | $9.09B | $624M | $8.15B | $437M | $9.18B | $618M | $9.56B | $585M | $9.87B | $625M | $8.62B | $431M |
| QoQ Change | — | -91.8% | >999% | -90.9% | >999% | -90.8% | +890.2% | -92.8% | >999% | -91.0% | >999% | -90.6% | +990.7% | -91.0% | +891.1% | -93.6% | >999% | -91.4% | >999% | -91.8% | >999% | -92.3% | >999% | -94.7% | >999% | -93.5% | >999% | -93.4% | >999% | -93.1% | >999% | -94.6% | >999% | -93.3% | >999% | -93.9% | >999% | -93.7% | >999% | -95.0% |
| YoY Change | — | — | — | — | — | — | — | — | +1.0% | -90.9% | -0.8% | -90.7% | -0.1% | -91.0% | -2.1% | -93.7% | +5.9% | -90.9% | +3.8% | -91.5% | +19.8% | -90.8% | +22.0% | -93.5% | +20.1% | -92.2% | +23.2% | -91.8% | +10.9% | -92.4% | +9.4% | -94.1% | +9.4% | -92.6% | +12.4% | -93.1% | +8.6% | -93.1% | +5.8% | -94.7% |
Range$392M – $9.87B
CAGR-24.3%
Avg YoY Growth-41.5%
Median YoY Growth-46.4%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's otezla — total revenues?
- Amgen (AMGN) reported otezla — total revenues of $431M in Q1 2026.
- How has Amgen's otezla — total revenues changed year-over-year?
- Amgen's otezla — total revenues decreased by 94.7% year-over-year, from $8.15B to $431M.
- What does otezla — total revenues mean?
- The total amount of money earned from sales of a specific drug product.